• Journal of Ginseng Research
• /
• 제46권3호
• /
• pp.321-330
• /
• 2022

Coronavirus has been spreading rapidly around the world since it broke out in China in 2019. Respiratory diseases caused by coronavirus infection cause various diseases ranging from asymptomatic subclinical infections to severe pneumonia and cardiovascular complications, leading to death. In this regard, natural products are being studied to prevent various diseases caused by COVID-19. In current review, we would like to present mechanisms related to the inhibition of heart disease in ginseng and ginsenoside against SARS-CoV-2. In many previous studies, ginseng and ginsenoside are known to have antioxidant, blood flow improvement, improvement of vascular and heart function, blood pressure control, suppression of myocardial infarction and heart failure, and antiarrhythmia. Therefore, ginseng and ginsenoside have a possibility to suppress cardiovascular complications caused by COVID-19. Many of research provide evidence for ginseng and ginsenoside as treatments for the risk of cardiovascular complications. However, in this review, more specific contents on the proposition of the efficacy of ginseng and ginsenoside for COVID-19 should be presented. Therefore, we hope that researches to reduce cardiovascular complications of ginseng and ginsenoside for COVID-19 should be presented to reduce mortality for COVID-19.

• Journal of Ginseng Research
• /
• 제44권5호
• /
• pp.717-724
• /
• 2020

Background: Malignant arrhythmias require drug therapy. However, most of the currently available antiarrhythmic drugs have significant side effects. Ginsenoside Rg2 exhibits excellent cardioprotective effects and appears to be a promising candidate for cardiovascular drug development. So far, the oral toxicity and antiarrhythmic effects of Rg2 have not been evaluated. Methods: Acute oral toxicity of Rg2 was assessed by the Limit Test method in mice. Subchronic oral toxicity was determined by repeated dose 28-day toxicity study in rats. Antiarrhythmic activities of Rg2 were evaluated in calcium chloride-induced arrhythmic rats. Antiarrhythmic mechanism of Rg2 was investigated in arrhythmic rats and H9c2 cardiomyocytes. Results: The results of toxicity studies indicated that Rg2 exhibited no single-dose (10 g/kg) acute oral toxicity. And 28-day repeated dose treatment with Rg2 (1.75, 3.5 and 5 g/kg/d) demonstrated minimal, if any, subchronic toxicity. Serum biochemical examination showed that total cholesterol in the high-dose cohort was dramatically decreased, whereas prothrombin time was increased at Day 28, suggesting that Rg2 might regulate lipid metabolism and have a potential anticoagulant effect. Moreover, pretreatment with Rg2 showed antiarrhythmic effects on the rat model of calcium chloride induced arrhythmia, in terms of the reduced duration time, mortality, and incidence of malignant arrhythmias. The antiarrhythmic mechanism of Rg2 might be the inhibition of calcium influx through L-type calcium channels by suppressing the phosphorylation of Ca²⁺/calmodulin-dependent protein kinase II. Conclusion: Our findings support the development of Rg2 as a promising antiarrhythmic drug with fewer side effects for clinical use.

• 대한약리학회지
• /
• 제22권2호
• /
• pp.105-114
• /
• 1986

본 실험실에서는 민간요법으로 말라리아와 성병등의 치료제로 사용되어온 회양목(Buxus microphylla var. koreana Nakai)에서 steroid성 alkaloid인 cyclobuxine D와 nonalkaloid인 buxuletin을 분리하였다. Buxuletin의 가토에 있어서 이뇨작용에 대해서는 본 실험실에서 보고한바 있으며 cyclobuxine D의 약리작용에 대한 보고는 지금까지 전무한 상태이다. 본 실험에서는 새로운 항부정맥 약물의 밭견의 일환으로 cyclobuxine D의 적출 개구리 심장에 대한 작용과 마취시킨 흰쥐의 ECG와 심박동수에 대한 작용을 관찰하였다. Cyclobuxine D는 적출 개구리 심장에 대해 용량의존적 심근 수축력 감소를 나타냈으며 흰쥐에 있어서 현저한 심박동수 감소를 나타냈다. Cyclobuxine D는 흰쥐의 ECG에 있어서 PR interval과 P ${\alpha}T$ interval을 연장시키며, QRS complex와 PR interval의 심박동수에 대한 보상치인 PRc에 대해서는 고용량에서는 연장시키나 그 작용이 현저하지 않다. 이 결과로 보아 cyclobuxine D는 흰쥐의 ECG에서 A-V conduction과 ventricular depolarization에 주로 관여하는 것으로 사료 되며 이는 기존의 antiarrhythmic drugs과 비교해 볼 때 quinidine sulfate와 유사성이 있다고 추정된다.